AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 335572
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium phosphate (MSP) 1, 3, 5, 10, 20, 30 mg/kg
Trial: 335572
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate (MSS) 1, 3, 5, 10, 20, 30 mg/kg
Trial: 335572
Drug: MSP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSP and MSS (equal doses)
Trial: 335572
Drug: MSP 30
RxNorm normalized name: hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [MSP-Blu]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSP 30 mg/kg
Trial: 335572
Drug: MSP 40
RxNorm normalized name: hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [MSP-Blu]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSP 40 mg
Trial: 335572
Drug: MSS 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSS 80 mg
Trial: 335572
Drug: MSP 80
RxNorm normalized name: hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [MSP-Blu]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSP 80 mg
Trial: 335572
Drug: MSP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSP and MSS (equivalent doses)
Trial: 30978155
Drug: Intermittent PEG-Asparaginase
RxNorm normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent PEG-Asparaginase (3 doses at 6-week intervals)
Trial: 30978155
Drug: Continuous PEG-Asparaginase
RxNorm normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous PEG-Asparaginase (10 doses at 2-week intervals)
Trial: 28549923
Drug: Consistently sufficient
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consistently sufficient vitamin D group (25(OH)D >50 nmol/L at months 3 and 24)
Trial: 28549923
Drug: Fluctuating vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluctuating vitamin D group (25(OH)D >50 nmol/L at either point)
Trial: 28549923
Drug: Consistently insufficient
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consistently insufficient vitamin D group (serum 25(OH)D ≤50 nmol/L at months 3 and 24)
Trial: 19352339
Drug: Continuous adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuous adalimumab 40 mg every other week (e.o.w.)
Trial: 19352339
Drug: Continuous adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuous adalimumab 40 mg every week
Trial: 19352339
Drug: Induction dosing
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction dosing followed by reinitiation of adalimumab
Trial: 8355460
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) therapy
Trial: 15226773
Drug: Nutrition intervention
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition intervention (NI) - intensive, individualised nutrition counselling by a dietitian using a standard protocol and oral supplements if required
Trial: 9591224
Drug: tolcapone 200
RxNorm normalized name: tolcapone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolcapone 200 mg with immediate-release levodopa/carbidopa formulations
Trial: 9591224
Drug: tolcapone 200
RxNorm normalized name: tolcapone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolcapone 200 mg with controlled-release levodopa/carbidopa formulation
Trial: 7908624
Drug: Interferon-alpha (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (3 MU thrice weekly) for one year
Trial: 2892388
Drug: Oxprenolol and
RxNorm normalized name: oxprenolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol and non-beta-blocker treatment
Trial: 2892388
Drug: Beta-blocker-based therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker-based therapy
Trial: 31750855
Drug: Marine ω‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine ω‐3 fatty acid, 1 g daily (including eicosapentaenoic acid, 460 mg, and docosahexaenoic acid, 380 mg)
Trial: 31750855
Drug: Marine ω‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine ω‐3 fatty acid, 1 g daily
Trial: 25843054
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (1% THC)
Trial: 25843054
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose (4% THC)
Trial: 25843054
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (7% THC)
Trial: 23658394
Drug: 7-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal capsular polysaccharide, CRM197 conjugate vaccine (PCV7)
Trial: 21237188
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg of lutein and 1 mg of zeaxanthin daily
Trial: 19686995
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium phosphate (NaP) preparation (90 mL in divided doses)
Trial: 19686995
Drug: High-dose bisacodyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose bisacodyl preparation (6 tablets of 5mg bisacodyl) plus water lavage (2 L of water)
Trial: 9530159
Drug: Dichloroacetate (DCA)
RxNorm normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichloroacetate (DCA) 80 mg/kg
Trial: 2499527
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no CHPP‐M treatment)
Trial: 20592050
Drug: Initiating insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initiating insulin as part of the Treating To Target in Type 2 Diabetes (4-T) trial
Trial: 18320867
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/day plus esterified conjugated estrogens 0.312 mg/day
Trial: 7594334
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg q.d. (n = 10)
Trial: 7594334
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg b.i.d. (n = 10)
Trial: 2179066
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg after evening meal
Trial: 2179066
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg before evening meal
Trial: 2179066
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg with snacks allowed
Trial: 2179066
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg with snacks forbidden
Trial: 6783419
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid administration
Trial: 25567841
Drug: 40% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% of the standard dose of IPV intradermally
Trial: 25567841
Drug: 20% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% of the standard dose intradermally
Trial: 25567841
Drug: full standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: full standard dose intramuscularly
Trial: 25567841
Drug: 40% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% of the standard dose intramuscularly
Trial: 21887214
Drug: artemether-lumefantrine (A/L)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: artemether-lumefantrine (A/L)
Trial: 19454737
Drug: Other blood
RxNorm normalized name: Other blood products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other blood pressure lowering drugs
Trial: 19454737
Drug: Three drugs
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three drugs at half standard dose
Trial: 19454737
Drug: Other blood
RxNorm normalized name: Other blood products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other blood pressure lowering drugs (excluding non-cardioselective β blockers)
Trial: 17574482
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 5 ml of 5% NaOCl + 2.5 ml of 3.6% H(2)O(2)
Trial: 17574482
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 5 ml of 5% NaOCl + 2.5 ml of 17% ethylenediamine tetraacetic acid
Trial: 15043765
Drug: New-generation antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New-generation antipsychotics (risperidone, olanzapine, quetiapine, ziprasidone, sertindole, amisulpride, aripiprazole)
Trial: 15043765
Drug: New-generation antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New-generation antipsychotics
Trial: 3121836
Drug: 24 h
RxNorm normalized name: Immune 24 Hour +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 h infusion of phosphate
Trial: 3121836
Drug: 24 h
RxNorm normalized name: Immune 24 Hour +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 h infusion of calcium
Trial: 25391865
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 120 kVp with 350 mgI/ml iodinated contrast agent
Trial: 25391865
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 100 kVp with 350 mgI/ml iodinated contrast agent
Trial: 25391865
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: 100 kVp with 270 mgI/ml iodinated contrast agent
Trial: 23868011
Drug: Anastrozole (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (3 additional years of treatment)
Trial: 23868011
Drug: Nil (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nil (no additional treatment)
Trial: 16015270
Drug: Butter (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butter (40 g daily for 4 weeks)
Trial: 16015270
Drug: Cheese (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cheese (40 g daily for 4 weeks)
Trial: 11849857
Drug: Treatment >2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment >2 h after symptoms onset
Trial: 1665182
Drug: Lisinopril-hydrochlorothiazide (L/HCTZ)
RxNorm normalized name: fosinopril / hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril-hydrochlorothiazide (L/HCTZ)
Trial: 2789927
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of oxytocin
Trial: 25881049
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (transfuse if haemoglobin concentration <7.5 g/dl)
Trial: 25881049
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (transfuse if haemoglobin concentration <9 g/dl)
Trial: 17042886
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg/day) with lithium (1-1.2 mEq/L) + haloperidol (10 mg/day)
Trial: 17042886
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with lithium (1-1.2 mEq/L) + haloperidol (10 mg/day)
Trial: 10902861
Drug: Ferric trimaltol
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric trimaltol (four different pharmaceutical formulations)
Trial: 9068464
Drug: OBTM‐2 (bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBTM‐2 (bismuth subcitrate 240 mg, tetracycline 500 mg, metronidazole 400 mg four times daily for 2 days)
Trial: 9068464
Drug: OBTM‐7 (bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBTM‐7 (bismuth subcitrate 120 mg, tetracycline 500 mg, metronidazole 400 mg four times daily for 1 wk)
Trial: 8453956
Drug: rac-felodipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rac-felodipine (20 mg solution p.o.)
Trial: 8453956
Drug: rac-nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rac-nitrendipine (20 mg solution p.o.)
Trial: 8453956
Drug: nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine (20 mg solution p.o.)
Trial: 28985434
Drug: Oxytocin administration
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin administration (24 IU)
Trial: 29228315
Drug: nab-paclitaxel 125
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 125 mg/m2/gemcitabine 1000 mg/m2 d1,8 three times weekly (q3w)
Trial: 29228315
Drug: nab-paclitaxel 125
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 125 mg/m2/carboplatin AUC2 day 1,8 q3w
Trial: 27128532
Drug: One-quarter standard-dose
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-quarter standard-dose ticagrelor (22.5 mg BID for 7 days)
Trial: 27128532
Drug: Standard-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose clopidogrel (75 mg QD for 7 days)
Trial: 22623230
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of omega-3 ethyl esters for 1 month
Trial: 19353351
Drug: Salmeterol/Fluticasone Propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/Fluticasone Propionate combination (SFC)
Trial: 15716083
Drug: Levetiracetam 3000
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam 3000 mg/day (administered bid)
Trial: 11154059
Drug: Laser acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser acupuncture treatment
Trial: 8878586
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of hypericin and pseudohypericin
Trial: 8878586
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of Hypericum extract
Trial: 8878586
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of Hypericum extract
Trial: 1904750
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg ritanserin
Trial: 1904750
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg ritanserin
Trial: 1904750
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ritanserin
Trial: 6309882
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ketoconazole
Trial: 6309882
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ketoconazole (chronic administration)
Trial: 24864639
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of 2% prilocaine
Trial: 24864639
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of 2% prilocaine + 8 mg of dexamethasone (2 ml)
Trial: 24864639
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg 0.5% levobupivacaine
Trial: 17299059
Drug: Open-label adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Open-label adalimumab 40 mg every other week
Trial: 15214257
Drug: Lysine-fortified wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine-fortified wheat flour (3 g of lysine per kilogram for three months)
Trial: 10223239
Drug: C +
RxNorm normalized name: Probiotic + Colostrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C + D + T (Carboplatin 300 mg/m2, Dacarbazine 1 g/m2, Tamoxifen 20 mg/day)
Trial: 10223239
Drug: C +
RxNorm normalized name: Probiotic + Colostrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C + D (Carboplatin 300 mg/m2, Dacarbazine 1 g/m2)
Trial: 8536512
Drug: Pancreatic enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic enzyme substitution preparation
Trial: 2571460
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of vecuronium
Trial: 2571460
Drug: Hourly boluses
RxNorm normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hourly boluses of vecuronium
Trial: 224478
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus BCG
Trial: 27587469
Drug: Ipilimumab (single-dose)
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab (single-dose)
Trial: 24657311
Drug: Chemical imbalance
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical imbalance test feedback (bogus biological test results)
Trial: 31127467
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (AI)
Trial: 16330887
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (AI) after 2-3 years of tamoxifen
Trial: 16330887
Drug: Continuing aromatase
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing aromatase inhibitors (AI) after 5 years of tamoxifen
Trial: 11881981
Drug: Tenoxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam (20 mg single-dose and 12 days repeated-dose)
Trial: 9662319
Drug: Intracervical Foley
RxNorm normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical Foley catheter/intravaginal dinoprostone 4 mg every 4 hours
Trial: 947510
Drug: Weekly combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly combination of cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, and prednisone
Trial: 947510
Drug: Intermittent combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent combination of the same five drugs given in courses of 5 days repeated every 4 weeks
Trial: 947510
Drug: Adriamycin as
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin as a single agent every 3 weeks
Trial: 31599746
Drug: Aspirin group
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin group (discontinued thienopyridines for 1 week)
Trial: 20301883
Drug: Spironolactone therapy
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone therapy (25 mg/day for 20 days) in Group A (smoking patients)
Trial: 20301883
Drug: Spironolactone therapy
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone therapy (25 mg/day for 20 days) in Group B (non-smoking patients)
Trial: 17940723
Drug: Treatment slowing
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment slowing atrophy rate by 30%
Trial: 9736234
Drug: Treatment partly
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment partly in a training apartment with problem-based education and special therapeutic support
Trial: 3190970
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate 75 mg kg‐1
Trial: 3190970
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate 25 mg kg‐1